Docket No.: MLA.028NP Page 1 of 1

Please Direct All Correspondence to Customer Number 20995

SUPPLEMENTAL SUBMISSION

Applicant

Emile M. Bellott, et al.

App. No

10/584,821

Filed

March 13, 2008

For

SMMR (SMALL MOLECULE

METABOLITE REPORTERS) FOR

USE AS IN VIVO GLUCOSE

BIOSENSORS

Examiner

Bin Shen

Art Unit

1794

Conf. No.

5573

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Applicant herewith submits a subsequent submission in addition to the submission dated December 21, 2010:

(X) A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated June 25, 2010 in two (2) pages.

The Commissioner is hereby authorized to charge any additional fees which may be required, now or in the future, or credit any overpayment, to Account No. 11-1410.

Dated: December 22, 2010

By: Grang n. Sr

Lindsey N. Singeo

Registration No. 61,365

Attorney of Record

Customer No. 20995

(949) 760-0404

10204199

CERTIFICATE OF EFS WEB TRANSMISSION

I hereby certify that this correspondence, and any other attachment noted on the automated Acknowledgement Receipt, is being transmitted from within the Pacific Time zone to the Commissioner for Patents via the EFS Web server on:

December 22,2010

(Date)

Lindsey N. Singeo, Reg. No. 61,365

Notice to Comply

Application No. 10584821	Applicant(s) BELLOTT ET AL.
Examiner BIN SHEN	Art Unit 1657

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING **NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or a	amino acid sequence	disclosure conta	ained in this a	pplication does n	ot comply w	ith the
requirements for such a	a disclosure as set for	th in 37 C.F.R.	1.821 - 1.825	for the following	reason(s):	

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):					
\boxtimes	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).				
\boxtimes	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).				
\boxtimes	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).				
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."				
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).				
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).				
\boxtimes	7. Other: Sequences in Fig. 34 of the Drawings need to be identified with a sequence identifier (SEQ ID NO#), a "Sequence Listing", its computer readable copy, and a statement that the content of the paper and computer readable copies are the same should be provided.				
Αp	oplicant Must Provide:				
\boxtimes	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".				
\boxtimes	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application.				
\boxtimes	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).				
For questions regarding compliance to these requirements, please contact:					
	For Rules Interpretation, call (571) 272-0731 or (571) 272-0951 For CRF Submission Help, call (571) 272-2510 PatentIn Software Program Support				
	Technical Assistance.1-866-217-9197 or 703-305-3028 or 571-272-6845 PatentIn Software is Available At www.USPTO.gov				

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY